Actelion ‘Day of Reckoning’ for Macitentan Overshadows Earnings

Actelion ‘Day of Reckoning’ for Macitentan Overshadows Earnings

Actelion Pharmaceuticals Ltd/copyright 2011 via Bloomberg

Investors will be looking for evidence that Actelion’s experimental lung drug, macitentan, can replace Tracleer, the pill that accounts for 87 percent of the company’s sales and starts losing patent protection in 2016.